Zydus Therapeutics Inc.
Clinical trials sponsored by Zydus Therapeutics Inc., explained in plain language.
US subsidiary of Zydus Lifesciences, developing pharmaceutical products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New hope for rare liver disease: drug aims to slow damage
Disease control Recruiting nowThis long-term study tests whether saroglitazar magnesium can prevent serious liver complications in people with primary biliary cholangitis (PBC), a rare autoimmune liver disease. About 386 adults already on standard treatment will receive either the drug or a placebo. The goal …
Phase: PHASE3 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New ALS drug usnoflast enters key trial to slow deadly disease
Disease control Recruiting nowThis study tests whether the drug usnoflast can slow the progression of ALS, a severe nerve disease that causes muscle weakness and breathing problems. About 240 adults with ALS will receive either usnoflast or a placebo for 36 weeks. Researchers will measure changes in daily fun…
Phase: PHASE2 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New drug study aims to understand how liver disease affects medication
Knowledge-focused Recruiting nowThis early-stage study will test a drug called saroglitazar magnesium in 6 adults with moderate liver scarring (cirrhosis) caused by cholestatic liver disease. The main goal is to see how the drug moves through the body and if it is safe when taken every other day. Participants w…
Phase: PHASE1 • Sponsor: Zydus Therapeutics Inc. • Aim: Knowledge-focused
Last updated Jul 30, 2026 00:00 UTC
-
Liver drug study seeks to understand how body processes medication in scarred livers
Knowledge-focused Recruiting nowThis study looks at how the drug Saroglitazar is processed in people with mild, moderate, or severe liver scarring (cirrhosis) caused by cholestatic liver disease. About 30 adults will take the drug once daily for 28 days. The goal is to measure drug levels in the blood and check…
Phase: PHASE1 • Sponsor: Zydus Therapeutics Inc. • Aim: Knowledge-focused
Last updated Jul 30, 2026 00:00 UTC